The Frontiers Research Topics : MEDICIS-Promed, Advances in Radioactive Ion Beams for Nuclear Medicine is now published. It can be downloaded from there.
The half-life of Tb-155 produced at MEDICIS has been revised and is now published by S. Collins et al. in Applied Radiation and Isotope. High molar activity Sm-153 was 1st used in Targeted Radionuclide Therapy and theranostics (MED-025) by M. Ooms et al, as presented at TERACHEM.
A third collaboration meeting took place today in the French ANR project REPARE, to review the progresses on the development of a high power Bi target for the production of At-211.
1st projects have been selected in PRISMAP-The European medical isotope programme.
Plenary presentation on new developments exploiting isotope mass separation in nuclear medicine presented at the 1st AccConf'22 at IAEA.
MEDICIS restarts its program today. Mass separation will be applied to purify and separate Sm-153 from a target produced at BR2. Some details on the project here.
- tenure-track position in the superheavy element chemistry department at GSI Darmstadt, Germany. 13/11/22. Prof. C.E. Duellman.
- PSI-FELLOW-III-3i / Postdoctoral Fellows (f/m/d) : R&D of laser ionization and mass separation for ISOL radionuclide production (IMPACT facility initiative, https://www.psi.ch/en/impact), to be extended [ into a tenure-track permanent scientist position for TATTOOS in 2025 psi-fellow-fmd, 30/11/22 24:00 CET. Contacts Nick van der Meulen.
A KNOWLEDGE TRANSFER SUCCESS STORY